China's Ascentage Pharma gets $150m in Series C funding
Ascentage Pharma, a Chinese biopharmaceutical company primarily focused on treatments for cancer, has raised $150 million in Series C funding.
The round was led by YuanMing Capital – a healthcare specialist that focuses on China-US cross-border deals – and Oriza Seed Venture Capital, a unit of Oriza Holdings. Both are existing investors in...
More on Greater China
Latest News
Buyout funds: Growth paradigm
Most traditional large-cap buyout funds have become hybrids in Asia, taking minority stakes in businesses to generate deal flow in certain markets and to harness regional growth trends
Addor raises $241m for second China healthcare fund
Addor Capital – a Chinese VC firm backed by Jiangsu High-Tech Investment Group, also known as Govtor Capital – has raised RMB1.56 billion ($241 million) for its second renminbi-denominated healthcare fund.
India's Trifecta closes venture debt fund at $140m
India’s Trifecta Capital has closed its second venture debt fund with $140 million in commitments. The firm raised about $68.4 million for its debut vehicle in 2017.
Japan space robotics start-up gets $17m
Gitai, a Japanese start-up developing a humanoid general-purpose work robot for use in space, has secured a JPY1.8 billion ($17 million) Series B round from local VCs.